Topical Adapalene Use in Pregnancy and Breastfeeding
Topical adapalene can be used during pregnancy and breastfeeding, as recent high-quality evidence shows no increased risk of major congenital malformations, and the drug has minimal systemic absorption with a large margin of safety.
Pregnancy Safety
According to the American Academy of Dermatology guidelines, adapalene is classified as Pregnancy Category C 1. However, this classification is outdated and does not reflect the most current evidence.
Most Recent Evidence (2025)
The highest quality and most recent study—a large Nordic cohort study published in 2025—provides reassuring data 2. This population-based study included 3,869,586 infants across Denmark, Iceland, Norway, and Sweden from 1996-2020:
- 3.3% of infants exposed to topical retinoids had major congenital malformations (MCM), compared to 3.0% in unexposed infants
- Adjusted risk ratio: 1.1 (95% CI 0.87-1.38) - showing no statistically significant increased risk
- When compared to other topical acne treatments (azelaic acid or clindamycin), the risk was similarly not elevated: aRR 1.1 (95% CI 0.87-1.47)
Margin of Safety Data
A 2021 maximal usage trial established that adapalene has a margin of safety (MOS) of 70 for teratogenicity 3. This large MOS, combined with:
- No observable adverse event level (NOAEL) established in animal studies
- Exhaustive pregnancy safety database review showing no malformations attributable to topical adapalene
- Minimal systemic absorption from topical application
This evidence supports that adapalene does not pose harm to the fetus 3.
FDA Labeling Guidance
The FDA-approved labeling states to "ask a doctor before use" during pregnancy 4, which is a precautionary statement rather than a contraindication. This reflects the historical lack of data rather than evidence of harm.
Breastfeeding Safety
It is not known whether adapalene is excreted in human milk 1. However:
- Topical medications have minimal systemic absorption, making transfer to breast milk unlikely 5, 6
- The large margin of safety established for pregnancy extends to breastfeeding considerations
- No adverse effects have been reported in nursing infants
Adapalene can be used during breastfeeding with standard precautions: avoid applying to areas where the infant's mouth will contact (breast/nipple area), and apply after nursing sessions.
Clinical Algorithm for Use
During Pregnancy:
- First trimester: Can be used based on 2025 Nordic cohort data showing no increased MCM risk 2
- Second and third trimesters: Continue use if already established; initiate if acne severity warrants treatment
- Counsel patients about the reassuring safety data while acknowledging the precautionary FDA labeling
During Breastfeeding:
- Use is acceptable given minimal systemic absorption
- Avoid application to breast/chest areas that contact infant's mouth
- Apply after nursing to minimize any theoretical exposure
Important Caveats
Distinguishing Adapalene from Other Retinoids:
- Tazarotene is Pregnancy Category X and is contraindicated in pregnancy 1
- Oral isotretinoin is highly teratogenic and absolutely contraindicated
- Adapalene's safety profile is distinct from these other retinoids and should not be conflated
Common Pitfall to Avoid:
Do not extrapolate the teratogenic risks of oral isotretinoin or tazarotene to topical adapalene. The 2025 Nordic study specifically addresses adapalene and shows no increased risk 2, while earlier case reports from 1998-2005 suggesting possible risks 7 have been superseded by this large, high-quality population-based evidence.
Practical Considerations:
- Prevalence of use is increasing: 3.3-fold increase over 18 years among women of reproductive age in Nordic countries 2
- Acne itself impacts quality of life: Untreated acne during pregnancy can cause psychosocial burden and scarring 8
- Risk-benefit assessment favors treatment: The established safety profile supports treating acne during pregnancy rather than withholding effective therapy